nAbbing SARS-CoV-2 variants

Written by Francesca Lake (Editor-in-Chief)

Neutralizing antibodies for different SARS-CoV-2 variants

New SARS-CoV-2 variants mean new neutralizing antibodies to deal with them.  With the COVID-19 pandemic on its third wave in some countries, the rise of variants has triggered a new wave of research into neutralizing antibodies, in a bid to maintain – or at least gain – control of the virus.   The new variants exhibit mutations in the receptor-binding domain (RBD) of the spike protein, which has been a mainstay for drug developers thus far. Studies have demonstrated that neutralizing antibodies are less efficacious against variants with mutations in the RBD – which include the B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa) and P.1 (first identified in...

To view this content, please register now for access

Become a member of BioTechniques for FREE to receive:

  • Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
  • The latest news delivered straight to your inbox when you want it
  • Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
  • Priority registration to webinars, panel discussions and events
  • Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!